MIT Biotechnology Group

Multiple job openings at Agios

Agios (agios.com) is a biopharmaceutical company committed to applying its scientific leadership in cellular metabolism to transform the lives of patients with cancer and rare genetic disorders. On August 1, 2017 we reached a key milestone when the U.S. Food and Drug Administration approved Idhifa (enasidenib/AG-221) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. We are growing rapidly with a diverse robust pipeline. We have multiple first-in-class product candidates in late-stage clinical development including AG-120 for AML. CEO, David Schenkein, formerly of Genentech and Millennium, was voted one of FierceBiotech's Top 25 Most Influential Biopharmaceutical Leaders in 2015.

Agios currently has multiple positions open, shown below. See their job website for detailed descriptions.

Lab and Operations Manager, Clinical Biomarker

 

Biology

AD, Clinical Biomarker

 

Biology

Research Associate/Senior Research Associate

Biology

Associate Scientist, MIO

Biology

Senior Research Associate, MIO

Biology

Scientist, Biophysics

Biochemistry

Senior Scientist, Enzymology

Biochemistry

AD, Regulatory Affairs CMC

Regulatory

Senior Scientist, Discovery DMPK

 

DMPK

Scientist/Senior Scientist, PK/PD Modeling

 

DMPK

AD, Biostatistics

Statistics&DM

AD, Clinical Science

Clinical Development

Leave a Reply